Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12254998 | 0.77 | ESR2 (0.47) | ESR1ESR2MAOAMAOBCYP19A1 | |
| SCHEMBL3415086 | 0.75 | MAOA (0.45) | ESR1ESR2MAOAMAOBCYP19A1 | |
| SCHEMBL13090322 | 0.75 | ALOX12 (0.44) | ESR1ESR2GSK3BALOX12SIRT1 | |
| SCHEMBL1428288 | 0.68 | ALDH1A1 (0.53) | ESR1ESR2MAOAMAOBCYP19A1 | |
| SCHEMBL31270617 | 0.68 | ESR2 (0.50) | ESR1ESR2MAOAMAOBCYP19A1 | |
| SCHEMBL614132 | 0.68 | ESR2 (0.50) | ESR1ESR2MAOAMAOBCYP19A1 | |
| SCHEMBL12023218 | 0.68 | ESR2 (0.45) | ESR1ESR2MAOAMAOBCYP3A4 | |
| SCHEMBL5890294 | 0.68 | NQO1 (0.62) | ESR1ESR2CYP3A4MEN1KMT2A | |
| SCHEMBL5712617 | 0.67 | MMP3 (0.47) | ESR1ESR2MEN1KMT2AHSD17B1 | |
| SCHEMBL31545406 | 0.67 | MAPT (0.50) | ESR1ESR2MAOAMAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | NOXOPHARM LIMITED (AU) | 2023-01-24 | — | — | US | disclosed |
| US-11229703-B2 | Radiotherapy improvements | NOXOPHARM LIMITED (AU) | 2022-01-25 | — | — | US | disclosed |
| EP-3939583-A1 | IMPROVEMENTS IN CANCER TREATMENT WITH ISOFLAVONOIDS | Noxopharm Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| US-20210338576-A1 | CANCER TREATMENT | NOXOPHARM LIMITED (AU) | 2021-11-04 | — | — | US | disclosed |
| US-20210275493-A1 | IMMUNO-ONCOLOGY THERAPY USING ISOFLAVONE COMPOUNDS | NOXOPHARM LIMITED (AU) | 2021-09-09 | — | — | US | disclosed |
| US-20190282540-A1 | TARGETED DRUG DELIVERY | NOXOPHARM LIMITED (AU) | 2019-09-19 | — | — | US | disclosed |
| US-20190262451-A1 | RADIOTHERAPY IMPROVEMENTS | NOXOPHARM LIMITED (AU) | 2019-08-29 | — | — | US | disclosed |
| US-20190160004-A1 | IMPROVEMENTS IN CANCER TREATMENT | NOXOPHARM LIMITED (AU) | 2019-05-30 | — | — | US | disclosed |
| US-20190117618-A1 | ISOFLAVONOID COMPOSITION WITH IMPROVED PHARMACOKINETICS | NOXOPHARM LIMITED (AU) | 2019-04-25 | — | — | US | disclosed |
| US-20190117620-A1 | CHEMOTHERAPY IMPROVEMENTS | NOXOPHARM LIMITED (AU) | 2019-04-25 | — | — | US | disclosed |
| US-20110212989-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-20110212989-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LTD (AU) | 2011-09-01 | — | — | US | disclosed |
| US-7915308-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7915308-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
| US-7202273-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282540-A1 | TARGETED DRUG DELIVERY | NTRK1, SI, TIE1 | ESR1 768/4885ESR2 325/4885MAOA 1807/4885 |
| US-20190117620-A1 | CHEMOTHERAPY IMPROVEMENTS | TP53, GSTA1, TOP2B | ESR1 438/4885ESR2 355/4885MAOA 3164/4885 |
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | SI, CYP51A1, CYP19A1 | ESR1 166/4885ESR2 137/4885MAOA 1810/4885 |
| US-20190160004-A1 | IMPROVEMENTS IN CANCER TREATMENT | TP53, HIF1AN, BRCA1 | ESR1 122/4885ESR2 39/4885MAOA 4247/4885 |
| US-20110212989-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, C1S, ESRRA | ESR1 96/4885ESR2 107/4885MAOA 1673/4885 |
| US-20210275493-A1 | IMMUNO-ONCOLOGY THERAPY USING ISOFLAVONE COMPOUNDS | IKZF1, IFNG, IL2 | ESR1 122/4885ESR2 121/4885MAOA 4292/4885 |
| US-20190262451-A1 | RADIOTHERAPY IMPROVEMENTS | MRE11, TP53, CHEK2 | ESR1 609/4885ESR2 258/4885MAOA 4377/4885 |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, ESRRA, ESRRB | ESR1 80/4885ESR2 83/4885MAOA 1619/4885 |
| US-20210338576-A1 | CANCER TREATMENT | TP53, HIF1AN, HIF1A | ESR1 77/4885ESR2 27/4885MAOA 3896/4885 |
| US-20190117618-A1 | ISOFLAVONOID COMPOSITION WITH IMPROVED PHARMACOKINETICS | SI, CYP51A1, CYP19A1 | ESR1 166/4885ESR2 137/4885MAOA 1810/4885 |
| US-11229703-B2 | Radiotherapy improvements | MRE11, TP53, CHEK2 | ESR1 609/4885ESR2 258/4885MAOA 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.